Rilpivirine pharmacokinetics without and with darunavir/ritonavir once daily in adolescents and young adults
© 2016 Wolters Kluwer Health, Inc. Background: Rilpivirine (RPV), a recently developed, once daily human immunodeficiency virus non-nucleoside reverse transcriptase inhibitor, is not currently approved for pediatric patients, but is sometimes prescribed for adolescents with multiple treatment failur...
Saved in:
Main Authors: | Foca M., Yogev R., Wiznia A., Hazra R., Jean-Philippe P., Graham B., Britto P., Carey V., King J., Acosta E., Cressey T. |
---|---|
Format: | Journal |
Published: |
2017
|
Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84969217101&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/41631 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Similar Items
-
Rilpivirine pharmacokinetics without and with darunavir/ritonavir once daily in adolescents and young adults
by: Marc Foca, et al.
Published: (2018) -
Pharmacokinetics of once-daily darunavir/ ritonavir with and without etravirine in human immunodeficiency virus-infected children, adolescents, and young adults
by: Larson K., et al.
Published: (2017) -
Pharmacokinetics of once-daily darunavir/ ritonavir with and without etravirine in human immunodeficiency virus-infected children, adolescents, and young adults
by: Kajal B. Larson, et al.
Published: (2018) -
Pharmacokinetics of darunavir/ritonavir with etravirine both twice daily in human immunodeficiency virus-infected adolescents and young adults
by: Tim R. Cressey, et al.
Published: (2018) -
Pharmacokinetics of darunavir/ritonavir with etravirine both twice daily in human immunodeficiency virus-infected adolescents and young adults
by: Tim R. Cressey, et al.
Published: (2018)